Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18193410 | 1.00 | CYP19A1 (0.33) | CYP19A1CA1CA2CA4CYP2D6 | |
| SCHEMBL16393774 | 1.00 | CYP19A1 (0.33) | CYP19A1CA1CA2CA4CYP2D6 | |
| SCHEMBL10601516 | 1.00 | CYP19A1 (0.33) | CYP19A1CA1CA2CA4CYP2D6 | |
| SCHEMBL97211 | 0.95 | — | — | |
| SCHEMBL11624219 | 0.85 | — | — | |
| SCHEMBL517915 | 0.82 | ALDH1A1 (0.30) | — | |
| SCHEMBL13515822 | 0.82 | ADH1A (0.33) | — | |
| SCHEMBL12834896 | 0.80 | — | — | |
| SCHEMBL15186982 | 0.79 | ADH1A (0.36) | — | |
| SCHEMBL7906079 | 0.76 | CA1 (0.33) | CYP19A1CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1025 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788353-B1 | CAGE AMINE LIGANDS FOR METALLO-RADIOPHARMACEUTICALS | Clarity Pharmaceuticals Ltd (AU) | 2022-05-18 | — | — | EP | claimed |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-21 | — | — | US | claimed |
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-07 | — | — | US | claimed |
| US-20060211860-A1 | Compounds for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-1666452-A2 | Compounds to treat Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| US-7030239-B2 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | claimed |
| EP-1299352-B1 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2005-12-28 | — | — | EP | claimed |
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | claimed |
| CN-1164680-C | Wear-resistant self-lubricating polybutanediol terephthalate and its prepn | 清华大学 | 2004-09-01 | — | — | CN | claimed |
| JP-2004502669-A | — | — | 2004-01-29 | — | — | JP | claimed |
| EP-1299352-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2003-04-09 | — | — | EP | claimed |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| EP-1265849-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2002-12-18 | — | — | EP | claimed |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | claimed |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-07 | — | — | US | claimed |
| WO-2002002506-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2002002512-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2001070672-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | claimed |
| US-4826993-A | Substituted diazolidinones | ELI LILLY AND COMPANY (US) | 1989-05-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | PSEN1, PSEN2, BACE1 | CYP19A1 27/4885CA1 125/4885CA2 2204/4885 |
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BCHE | CYP19A1 35/4885CA1 267/4885CA2 2123/4885 |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | CYP19A1 202/4885CA1 268/4885CA2 1554/4885 |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | CYP19A1 32/4885CA1 148/4885CA2 1158/4885 |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BACE1 | CYP19A1 19/4885CA1 111/4885CA2 1203/4885 |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, CHAT | CYP19A1 308/4885CA1 192/4885CA2 2257/4885 |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | CYP19A1 27/4885CA1 125/4885CA2 2204/4885 |
| US-20060211860-A1 | Compounds for the treatment of Alzheimer's disease | PSEN2, PSEN1, CHAT | CYP19A1 363/4885CA1 574/4885CA2 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.